Heron Therapeutics Inc. (NASDAQ:HRTX) was the target of a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 14,778,780 shares, an increase of 18.5% from the September 15th total of 12,476,147 shares. Approximately 38.2% of the shares of the company are short sold. Based on an average daily volume of 509,083 shares, the short-interest ratio is currently 29.0 days.

HRTX has been the topic of several recent research reports. Cantor Fitzgerald reissued a “buy” rating and issued a $41.00 price target on shares of Heron Therapeutics in a report on Wednesday, August 3rd. Jefferies Group reaffirmed a “buy” rating and set a $46.00 target price on shares of Heron Therapeutics in a research note on Wednesday, July 27th. Cowen and Company reaffirmed a “buy” rating on shares of Heron Therapeutics in a research note on Saturday, July 9th. Leerink Swann reaffirmed a “buy” rating on shares of Heron Therapeutics in a research note on Monday, June 27th. Finally, Brean Capital reaffirmed a “buy” rating and set a $55.00 target price on shares of Heron Therapeutics in a research note on Saturday, August 13th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. Heron Therapeutics currently has an average rating of “Buy” and a consensus price target of $42.29.

In related news, insider Robert Rosen sold 100,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 10th. The stock was sold at an average price of $23.30, for a total value of $2,330,000.00. Following the sale, the insider now owns 102,640 shares of the company’s stock, valued at approximately $2,391,512. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 20.31% of the stock is owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in the stock. Cormorant Asset Management LLC raised its stake in Heron Therapeutics by 3.8% in the first quarter. Cormorant Asset Management LLC now owns 1,750,000 shares of the biotechnology company’s stock valued at $33,233,000 after buying an additional 64,281 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Heron Therapeutics by 6.0% in the first quarter. JPMorgan Chase & Co. now owns 348,685 shares of the biotechnology company’s stock valued at $6,622,000 after buying an additional 19,737 shares in the last quarter. VHCP Management II LLC bought a new stake in Heron Therapeutics during the first quarter valued at $7,708,000. California State Teachers Retirement System raised its stake in Heron Therapeutics by 7.6% in the second quarter. California State Teachers Retirement System now owns 66,632 shares of the biotechnology company’s stock valued at $1,203,000 after buying an additional 4,732 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its stake in Heron Therapeutics by 3.2% in the second quarter. Bank of New York Mellon Corp now owns 147,986 shares of the biotechnology company’s stock valued at $2,672,000 after buying an additional 4,579 shares in the last quarter.

Heron Therapeutics (NASDAQ:HRTX) opened at 15.70 on Thursday. Heron Therapeutics has a 12 month low of $15.13 and a 12 month high of $31.32. The stock’s 50 day moving average price is $18.23 and its 200 day moving average price is $18.89.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Monday, August 8th. The biotechnology company reported ($1.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.96) by $0.21. Equities research analysts expect that Heron Therapeutics will post ($4.39) EPS for the current year.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

5 Day Chart for NASDAQ:HRTX

Receive News & Stock Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related stocks with our FREE daily email newsletter.